Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML

December 9th 2023

Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.

Real-World Analysis Sheds Light on Safety and Efficacy of Teclistamab in R/R Multiple Myeloma

December 9th 2023

The T-cell redirecting bispecific antibody teclistamab-cqyv demonstrated efficacy and a tolerable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma consistent with that of those enrolled in the phase 2 MajesTEC-1 trial.

All-Oral Arsenic Trioxide, All-Trans Retinoic Acid/Ascorbic Acid Proves Effective, Safe in Acute Promyelocytic Leukemia

December 9th 2023

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

FDA Approves Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

December 6th 2023

The FDA has approved iptacopan (Fabhalta) for use in adult patients with paroxysmal nocturnal hemoglobinuria.

Looking Ahead to Upcoming Presentations at ASH 2023

December 5th 2023

Expert insights into the evolving treatment landscape for chronic lymphocytic leukemia (CLL), emphasizing upcoming clinical data to be presented at ASH 2023.

CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma

December 5th 2023

Dr. Locke reviews the latest data from ZUMA-7 and TRANSFORM studies, evaluating CAR T in the second line setting for R/R LBCL.

Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

December 5th 2023

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Challenges in CAR T-Cell Therapy for Lymphoma

December 5th 2023

Delve into the challenges of CAR T-cell therapy access and explore the biology behind treatment responses and relapses in lymphoma patients.

Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

December 5th 2023

Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy.

FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas

December 4th 2023

The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCL

November 28th 2023

Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.

Hematologists Dive into the Current Treatment Landscape

November 28th 2023

Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.

CAR T-Cell Therapy’s Impact on Lymphoma Management

November 28th 2023

Gain insights into CAR T-cell therapy's impact on lymphoma treatment through a historical perspective and mechanism of action.

Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies

November 28th 2023

Discover cutting-edge cellular therapeutics, CAR T-cell therapy, and bispecific strategies for treating lymphoma patients in clinical trials.

FDA Approval Sought for Obe-Cel in Relapsed/Refractory B-ALL

November 27th 2023

A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies

November 22nd 2023

Expert insight into current treatment strategies and emerging therapies for diffuse large B-cell lymphoma, a challenging malignancy.

Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators

November 22nd 2023

Explore the diverse ways large B-cell lymphoma can manifest, the diagnostic process, and prognostic indicators for effective management.

Dr Phillips on the Management of Toxicities Associated With CAR T-Cell Therapy

November 21st 2023

Adrienne Phillips, MD, MPH, discusses the management of toxicities associated with CAR T-cell therapy across hematologic malignancies.

Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies

November 15th 2023

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.